Literature DB >> 22959094

Intragastric acidity during the first day following administration of low-dose proton pump inhibitors: a randomized crossover study.

Sachio Hata1, Makoto Arai, Daisuke Maruoka, Takeshi Tanaka, Tomoaki Matsumura, Takuto Suzuki, Tomoo Nakagawa, Tatsuro Katsuno, Fumio Imazeki, Osamu Yokosuka.   

Abstract

OBJECTIVE: Low-dose proton pump inhibitors (PPIs) are often administrated as maintenance therapy for gastroesophageal reflux disease (GERD) and on-demand PPI therapy is a viable option for long-term management of GERD. The aim of this study is to investigate intragastric acidity during the first day following the administration of low-dose PPIs. SUBJECTS AND METHODS: The study employed a crossover design. The subjects were 10 healthy volunteers who were administrated lansoprazole 15 mg (orally disintegrating) or rabeprazole 10mg. All subjects underwent pH monitoring with a wireless system during the first day after PPI administration.
RESULTS: There was no significant difference in the average intragastric pH during the first day of administration of lansoprazole and rabeprazole (3.3±1.1 vs. 3.2±0.7, paired t test), although the pH was significantly higher with both drugs as compared with the baseline (1.8±0.4, P<0.01). The pH 4 holding time ratio during the first day showed no significant difference between lansoprazole and rabeprazole (35.2±22.4% vs. 34.3±15.0%), and was also significantly higher than at baseline (0.35±1.73%, P<0.01). The two PPIs differed with respect to the peak of the pH 4 holding time ratio.
CONCLUSIONS: Lansoprazole 15 mg and rabeprazole 10 mg showed sufficient inhibition of intragastric acidity during the first day after PPI administration and the effects did not differ between drugs, although there was a difference in their time at which the peak effects were reached.
Copyright © 2012 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22959094     DOI: 10.1016/j.clinre.2012.07.010

Source DB:  PubMed          Journal:  Clin Res Hepatol Gastroenterol        ISSN: 2210-7401            Impact factor:   2.947


  3 in total

1.  Effect of Elevated pH on the Commercial Enteric-Coated Omeprazole Pellets Resistance: Patent Review and Multisource Generics Comparison.

Authors:  Valentyn Mohylyuk; Anna Yerkhova; Marina Katynska; Vitaliy Sirko; Kavil Patel
Journal:  AAPS PharmSciTech       Date:  2021-06-22       Impact factor: 3.246

Review 2.  The Safety of Appropriate Use of Over-the-Counter Proton Pump Inhibitors: An Evidence-Based Review and Delphi Consensus.

Authors:  David A Johnson; Philip O Katz; David Armstrong; Henry Cohen; Brendan C Delaney; Colin W Howden; Peter Katelaris; Radu I Tutuian; Donald O Castell
Journal:  Drugs       Date:  2017-04       Impact factor: 9.546

Review 3.  The role of vonoprazan in patients with erosive esophagitis.

Authors:  Mengyu Zhang; Yinglian Xiao; Minhu Chen
Journal:  Therap Adv Gastroenterol       Date:  2022-09-13       Impact factor: 4.802

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.